Kodiak Sciences shares rally as Zenkuda demonstrates clinical efficacy in wet AMD, establishing a potential new standard of care with durable 24-week dosing intervals for a majority of patients.
Zenkuda met primary endpoint with p=0.0007 and majority of patients on 24-week dosing, indicating a potential new standard of care, which is bullish for Kodiak Sciences.
Kodiak Sciences reported positive Phase 3 results for its lead candidate, Zenkuda, which met its primary endpoint with a p-value of 0.0007. The data highlights significant vision gains and retinal drying, with 54% of patients successfully maintained on a 6-month dosing schedule.
The trial results establish Zenkuda as a potential first-line treatment for wet age-related macular degeneration, offering a competitive advantage through durable 24-week dosing intervals.